VY-1706 in Alzheimer Disease: NCT07764146 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Recruiting
Recruitment status
18
Planned enrollment
2029-04-28
Primary-completion proxy
Executive view
NCT07764146 evaluates VY-1706 in Alzheimer Disease. The disclosed sponsor is Voyager Therapeutics, Inc., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is To characterize the safety and tolerability in participants with AD by Incidence of treatment emergent adverse events, changes from baseline in vital signs, physical and neurological exams and other safety measures, assessed over 52 weeks.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07764146 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Alzheimer Disease landscape. Drug & Asset MCP drug_fetch was queried for VY-1706, while Company & Deal Intelligence MCP organization_fetch was queried for Voyager Therapeutics, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07764146 | VY-1706 | Phase 1 / Recruiting | Voyager Therapeutics, Inc. | United States | To characterize the safety and tolerability in participants with AD by Incidence of treatment emergent adverse events… 52 weeks | 2029-04-28 |
| NCT07780383 | PRX-005 | Phase 1 / Not yet recruiting | Bristol Myers Squibb Co. | United States | Absolute bioavailability estimated from geometric mean ratio (GMR) of area under the concentration-time curve from time… Up to approximately 5 months | 2027-06-17 |
| NCT07768592 | E2511 | Phase 1 / Not yet recruiting | Eisai, Inc. | Geography not reported | Part A (Core Trial): Change from Baseline in [11C]MK-6884 Positron Emission Tomography (PET) Using Non-Displaceable Bin… Baseline up to Day 14 | 2030-05-06 |
| NCT07764679 | [18F]Fluorbetazine | Phase 3 / Recruiting | HTA Co., Ltd. | China | The sensitivity and specificity of PET imaging visual interpretation results compared to true standards after a single… 1 year | 2027-12-31 |
| NCT07757204 | Buntanetap | Phase 2/3 / Not yet recruiting | Annovis Bio, Inc. | Geography not reported | Safety of buntanetap 24 months of treatment | 2030-02-21 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07764146 is a Phase 1, recruiting study with 18 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment.
The primary endpoint is “To characterize the safety and tolerability in participants with AD by Incidence of treatment emergent adverse events, changes from baseline in vital signs, physical and neurological exams and other safety measures” over “52 weeks.” The retrieved endpoint description is: Incidence of treatment emergent adverse events, clinically significant changes from baseline in vital signs, physical and neurological exams, Columbia Suicide-Severity Rating Scale, Electrocardiogram, Clinical lab parameters and transthoracic echocardiogram.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 18 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Alzheimer Disease. These records do not establish direct evidence for NCT07764146 unless the registration number matches.
Randomized, Delayed Start, Double Blind, Parallel Group, Placebo Controlled, Multicenter Study of Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
Phase 2/3; n=216; Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog 14)(Mean) = -2 ADAS-Cog score (Standard Deviation, 5.20); Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog 14)(Mean) = -1.9 ADAS-Cog score (Standard Deviation, 5.59) Source: https://clinicaltrials.gov/ct2/show/results/NCT05267535
A Multiple Ascending Dose Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to…
Phase 1; n=34; Number of Participants Who Experienced an Adverse Event (AE) = 7 Participants ; Number of Participants Who Experienced an Adverse Event (AE) = 5 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05466422
ADVANCE-2: Addressing Dementia Via Agitation-Centered Evaluation 2: A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatm…
Phase 3; n=408; Cohen-Mansfield Agitation Inventory (CMAI)(Least Squares Mean) = -12.77 score on a scale (Standard Error, 0.921); Cohen-Mansfield Agitation Inventory (CMAI)(Least Squares Mean) = -13.85 score on a scale (Standard Error, 0.917) Source: https://clinicaltrials.gov/ct2/show/results/NCT05557409
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
VY-1706 is indexed as siRNA with TAU biology and a global stage of Phase 1. The asset profile lists Voyager Therapeutics, Inc. as an originator or developer.
Voyager Therapeutics, Inc. is indexed in United States with the website http://www.voyagertherapeutics.com. Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology. The record lists 27 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether VY-1706 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07764146
Protocol source: https://clinicaltrials.gov/study/NCT07764146
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
VY-1706 in Alzheimer Disease is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes To characterize the safety and tolerability in participants with AD by Incidence of treatment emergent adverse events, changes from baseline in vital signs, physical and neurological exams and other safety measures and 2029-04-28 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
